Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.85 |
| ▸ | RAF1 | P04049 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.85 |
| ▸ | HPGD | P15428 | 2/20 | 0.85 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.85 |
| ▸ | BRAF | P15056 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.85 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | SMO | Q99835 | 2/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388528 | 0.92 | MAPK14 (1.00) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL29354376 | 0.92 | MAPK14 (1.00) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL1424183 | 0.92 | MAPK14 (1.00) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL2978300 | 0.91 | MAPK14 (0.70) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL2979735 | 0.88 | MAPK14 (0.70) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL22066261 | 0.86 | MAPK14 (0.64) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL2975508 | 0.86 | MAPK14 (0.64) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL8163165 | 0.86 | MAPK14 (0.88) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL22025450 | 0.86 | MAPK14 (0.64) | MAPK14RAF1KDM4EALDH1A1MAPT | |
| SCHEMBL2976969 | 0.85 | MAPK14 (0.64) | MAPK14RAF1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | MAPK14 1775/4885RAF1 1052/4885KDM4E 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.